Reported 2 days ago
TD Cowen analyst Yaron Werber has reiterated a Buy rating for Legend Biotech Corporation (NASDAQ:LEGN), maintaining a price target of $62.00. Despite current supply constraints with its Carvykti product, the company is expected to navigate these issues by the end of 2025 through planned expansions. Legend Biotech anticipates meeting a sales target of $1.9 billion for fiscal year 2025, highlighting strong growth potential in its operational markets, including the US and China.
Source: YAHOO